4.5 Article

(-)-Epigallocatechin-3-Gallate Protects SH-SY5Y Cells Against 6-OHDA-Induced Cell Death through STAT3 Activation

期刊

JOURNAL OF ALZHEIMERS DISEASE
卷 17, 期 2, 页码 295-304

出版社

IOS PRESS
DOI: 10.3233/JAD-2009-1048

关键词

(-)-Epigallocatechin-3-gallate (EGCG); 6-Hydroxydopamine (6-OHDA); neuroprotection; Parkinson's disease; signal transducers and activators of transcription (STAT)

资金

  1. National Nature Science Foundation of China [30430280]
  2. Ministry of Sciences and Technology [2004BA702B02, 2006CB500701, 2006AA02A408, 2008ZX09312-014]

向作者/读者索取更多资源

As a natural product, (-)-Epigallocatechin-3-gallate (EGCG), has demonstrated remarkable neuronal protection by depressing oxidative stress in Parkinson's disease (PD). However, the molecular mechanisms underlying EGCG neuronal protection have not been clarified. Using 6-hydroxydopamine (6-OHDA)-treated human neuroblastoma SH-SY5Y cells as a PD cell model, we found that 6-OHDA can cause neuronal death by regulating the activity of STAT3. Pretreatment of SH-SY5Y cells with EGCG (0.1-10 mu M) significantly attenuated cell death induced by 6-OHDA. In addition, STAT3 activity decline induced by 6-OHDA in SH-SY5Y cells can be completely prevented by the presence of 1 mu M of EGCG, and neuronal cell proliferation can be stimulated by EGCG treatment. These results clearly demonstrate that the disruption of STAT3 signaling by 6-OHDA makes significant contribution to the neuronal death in PD, and the protection of EGCG on neurons against oxidative stress-induced cell death may result from the re-stimulation of STAT3 signaling pathway. Our study not only clarified the role of STAT3 signaling pathway in oxidative stress-induced neuronal cell death, but also identified its involvement in the protection mechanism of EGCG on neurons in PD. The data resulting from our study also suggest that STAT3 may serve as a potential therapeutic target for drug development in PD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据